The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)

Summary

This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks. The study will have a 1:1:1 randomization (CU06-1004 100mg: CU06-1004 200mg: CU06-1004 300mg).

Timeline

Start

2022-12-21

Primary completion

2023-05-31

Completion

2023-06-30

Drugs

Indications